FDA approves Purdue's controversial OxyContin for kids aged 11 to 16

Purdue Pharma now has FDA permission to market highly controversial opioid painkiller OxyContin to an even younger population. Late last week, the agency green-lighted the drug in patients aged 11 to 16 who haven't benefited enough from alternative therapies. The warnings and precautions for pediatric patients are the same as those for adults, the FDA said. More

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.